OSIRIS THERAPEUTICS, INC.

Delayed Nasdaq  - 
0.000000 USD    0.00%
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc

04/17/2019 | 09:06am EDT

COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris to Smith & Nephew plc (“Smith & Nephew”) through the consummation of a merger of Osiris with and into an indirect wholly-owned subsidiary of Smith & Nephew (the “Subsidiary”) without a vote of the Osiris stockholders in accordance with Section 3-106.1 of the Maryland General Corporation Law.  A majority of the outstanding shares of Osiris common stock were tendered in the tender offer.  In the second-step merger, each share of Osiris common stock that was not purchased by Smith & Nephew in the tender offer (other than shares directly owned by the Subsidiary or by any subsidiary of Osiris) has been converted into the right to receive $19.00 per share in cash, without interest, subject to any required withholding of taxes, which is the same cash price per share as was paid in the tender offer.  As a result of the merger, Osiris became an indirect wholly-owned subsidiary of Smith & Nephew and Osiris’ shares will cease to be traded on the NASDAQ Global Select Market.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, researches, develops, manufactures and commercializes regenerative medicine products intended to improve the health and lives of patients and lower overall healthcare costs. We have achieved commercial success with products in orthopedics, sports medicine and wound care, including the Grafix product line, Stravix®, BIO and Cartiform®. We continue to advance our research and development by focusing on innovation in regenerative medicine, including the development of bioengineered stem cell and tissue‑based products. Osiris®, Grafix®, GrafixPL®, GrafixPL PRIME, Cartiform®, and Prestige Lyotechnologysm are our trademarks. BIO is a trademark of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation. More information can be found on the Company’s website, www.osiris.com. (OSIR-G)

For additional information, please contact:
Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
OsirisPR@Osiris.com

 

Osiris High Res JPEG.jpg


© GlobeNewswire 2019
All news about OSIRIS THERAPEUTICS, INC.
2019Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
GL
2019OSIRIS SHAREHOLDER NOTICE : Faruqi & Faruqi, LLP Announces an Investigation of Osiris Ther..
PR
2019WeissLaw LLP Investigates Osiris Therapeutics, Inc.
PR
2019Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OS..
PR
2019ALERT : Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.
PR
2019OSIRIS THERAPEUTICS, INC. Rigrodsky & Long, P.A. Announces Investigation of Buyout
BU
2019Smith & Nephew to buy Osiris in regenerative products push
RE
2019OSIRIS THERAPEUTICS : Smith & Nephew expands in high growth regenerative medicine market t..
PR
2019Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
GL
2019HAGENS BERMAN : Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to ..
BU
More news
Managers and Directors
Samson Tom President & Chief Executive Officer
Laine Dyess Vice President-Sales
Heather Hill VP-Regulatory Affairs & Quality Assurance
Jeffrey Levin Vice President-Human Resources
Sector and Competitors
1st jan.Capi. (M$)
OSIRIS THERAPEUTICS, INC.40.67%0
GILEAD SCIENCES, INC.-12.33%80 075
REGENERON PHARMACEUTICALS, INC.7.98%71 235
VERTEX PHARMACEUTICALS22.20%66 136
WUXI APPTEC CO., LTD.-17.77%42 735
BIONTECH SE-36.77%39 612